CompletedPhase 2

Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain

United States20 participantsStarted 2020-01-06

Plain-language summary

Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in patients after mini-abdominoplasty

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Not pregnant
✓. Not breastfeeding
✓. Not planning to become pregnant during participation in the study
✓. Committed to the use of an acceptable form of birth control for the duration of the study until at least 30 days after administration of IP.

Mean (Peak) Plasma Concentration (Cmax)

Timeframe: Baseline through 120 hours after start of study drug administration

NCT IDNCT04182880

SponsorCali Pharmaceuticals LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-02-28

Results submitted2022-07-18